Nervous system

CWCI Analyzes California Workers’ Comp Inpatient Care

Retrieved on: 
Wednesday, January 31, 2024
Public Policy, Government, Insurance, Human Resources, State, Local, Managed Care, Surgery, Health, Professional Services, California Department, Manager, MDC, Connective tissue, Care Act 2014, Diagnosis, COVID, Human, Pregnancy, Nervous system, Inpatient care, HCAI, Respiratory system, Medi-Cal, Affordable Care Act, Knee, Hospital

A new analysis by the California Workers’ Compensation Institute (CWCI) uses data on 28.7 million inpatient hospital stays with 2012 through 2022 discharge dates compiled by the California Department of Health Care Access and Information (HCAI) to measure and compare the use of inpatient services and procedures covered by workers’ compensation, Medicare, Medi-Cal and private coverage.

Key Points: 
  • A new analysis by the California Workers’ Compensation Institute (CWCI) uses data on 28.7 million inpatient hospital stays with 2012 through 2022 discharge dates compiled by the California Department of Health Care Access and Information (HCAI) to measure and compare the use of inpatient services and procedures covered by workers’ compensation, Medicare, Medi-Cal and private coverage.
  • The most recent data suggest that many of those factors continue to help contain the volume of workers’ comp inpatient stays, as unlike the other systems where inpatient hospitalizations have rebounded after falling sharply in 2020 (the first year of the pandemic), workers’ comp inpatient stays have continued to drop.
  • With the recent decline in COVID-related hospitalizations, the distribution of workers’ comp inpatient stays by diagnosis shifted back toward pre-pandemic levels.
  • CWCI has issued a Research Update Report on its study, “Utilization of Inpatient Care in California Workers’ Compensation, 2012-2022.” CWCI members and subscribers can access the report and a summary Bulletin at www.cwci.org .

DFI Unveils Embedded System Module Equipped with Intel's Latest AI Processor to Enter the AI IPC Market

Retrieved on: 
Wednesday, January 31, 2024
Nervous system, DDR5, AI, GPU, COM Express, CPU, Temperature, SOM, SSD, Type 6, Ipcs, Fan (machine), Architecture, Intel, Ultra, NVM Express, NPU, DFI, LP, Video game

TAIPEI, Jan. 31, 2024 /PRNewswire/ -- DFI , the world's leading brand in embedded motherboards and industrial computers, is targeting the AI application market by launching the embedded system module (SOM) MTH968 equipped with the latest Intel® Core™ Ultra processor.

Key Points: 
  • TAIPEI, Jan. 31, 2024 /PRNewswire/ -- DFI , the world's leading brand in embedded motherboards and industrial computers, is targeting the AI application market by launching the embedded system module (SOM) MTH968 equipped with the latest Intel® Core™ Ultra processor.
  • It is the first product integrated with an NPU (Neural Processor Unit) processor, representing the official integration of AI with industrial PCs (IPCs).
  • With the expansion into AI IPC, DFI expects to inject new momentum into the AI edge computing market.
  • As 5G, edge computing, and remote control tech advance, IPCs directly handle complex tasks through AI edge computing.

TPGi® & Indeed Empower Job Seekers with Disabilities through Digital Accessibility

Retrieved on: 
Tuesday, January 30, 2024
Disability, Speech, Organization, Hearing, Nervous system, ARC, Employment, Cognition, Nursing

CLEARWATER, Fla., Jan. 30, 2024 /PRNewswire/ -- TPGi's Accessibility Management Platform, ARC, has been selected by Indeed, the world's number one job site, to ensure a compliant and usable experience for all job seekers, regardless of ability.

Key Points: 
  • Together, TPGi and Indeed are leading the charge to ensure that access to employment technology is accessible to all.
  • TPGi's ARC Platform empowers organizations to build sustainable accessibility programs, aligning teams across departments to achieve accessibility conformance and usability goals.
  • With over 350 million unique visitors every month, Indeed puts job seekers first, giving users free access to search for jobs, post resumes, and research employers.
  • "By providing accessible connections between all job seekers and employers, we are able to fulfill our mission to help people get jobs. "

Autonomix Medical, Inc. (NASDAQ: AMIX) Commences Trading on NASDAQ

Retrieved on: 
Monday, January 29, 2024
AMIX, Nervous system, Collateral damage, Disease, IPO, Pain

THE WOODLANDS, TX., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, announced its common stock will begin trading on the NASDAQ today, Monday, January 29, 2024 at approximately 10:30 am EST under the ticker symbol “AMIX.”

Key Points: 
  • THE WOODLANDS, TX., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, announced its common stock will begin trading on the NASDAQ today, Monday, January 29, 2024 at approximately 10:30 am EST under the ticker symbol “AMIX.”
    Lori Bisson, Chief Executive Officer of Autonomix, commented, “The successful closing of our IPO and trading on NASDAQ is a momentous milestone and the first step toward strengthening our market position.
  • NASDAQ provides a platform of enhanced visibility, liquidity and expanded shareholder base that we believe will play a key factor for the Company moving forward.
  • We are dedicated to dramatically improving the quality of millions of lives by empowering the nerve-directed treatments of tomorrow and we have positioned the Company to achieve transformational corporate and development milestones in 2024.
  • For more information about the Company’s technology, please visit autonomix.com .

Autonomix Medical, Inc. Announces Closing of $11.2 Million in Gross Proceeds from Initial Public Offering

Retrieved on: 
Friday, January 26, 2024
AMIX, Digital, Sale, Nervous system, Bevilacqua

THE WOODLANDS, TX., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the closing of its initial public offering of 2,234,222 shares of common stock priced at $5.00 per share. The gross proceeds to Autonomix, before deducting selling agent commissions and other offering expenses payable by Autonomix were $11,171,110. Autonomix expects its shares of common stock to begin trading on NASDAQ on Monday, January 29, 2024 at approximately 10:30 AM EST under the ticker symbol “AMIX.”

Key Points: 
  • The gross proceeds to Autonomix, before deducting selling agent commissions and other offering expenses payable by Autonomix were $11,171,110.
  • ArentFox Schiff LLP acted as counsel to Autonomix and Bevilacqua PLLC acted as counsel for the managing selling agent.
  • The offering was made only by means of an offering circular.
  • An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission (“SEC”) and has become qualified.

SEALSQ Unveils AIoT Strategy with WISeAI.IO at Davos AI Roundtable

Retrieved on: 
Thursday, January 18, 2024
Synthetic media, Rot, Semiconductor, Privacy, Internet, Research, Artificial intelligence, LAES, Ethics, Public policy, Policy, Literacy, Leverage, Safety, Algorithm, Ecosystem, Environment, Computer, Generative, Artificial intelligence of things, Ethicist, Anomaly, Post-quantum cryptography, Near-field communication, Nervous system, Responsibility, Control, PKI, Hotel Europe, Internet of things, Hacking, Medical device

Davos, Switzerland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- SEALSQ Corp ("SEALSQ" or "Company") (NASDAQ: LAES), a company that focuses on developing and selling Semiconductors, PKI and Post-Quantum technology hardware and software products, today announced its innovative AI strategy during the Artificial Intelligence (AI) Roundtable at Davos.

Key Points: 
  • Davos, Switzerland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- SEALSQ Corp ("SEALSQ" or "Company") (NASDAQ: LAES), a company that focuses on developing and selling Semiconductors, PKI and Post-Quantum technology hardware and software products, today announced its innovative AI strategy during the Artificial Intelligence (AI) Roundtable at Davos.
  • The AIoT system functions as the central brain of the SEALSQ Ecosystem, which currently consists of over 1.6 billion semiconductor powered devices.
  • In conjunction with its AI strategy announcement, SEALSQ hosted a successful roundtable discussion titled "Decentralization: AI Unleashed: Ensuring Safety and Leveraging Decentralization" at the Hotel Europe in Davos, featuring a diverse panel of experts, including AI researchers, ethicists, technology professionals, and policymakers.
  • Establishment of Ethical AI Guidelines: The roundtable emphasized the need for universal ethical standards in AI development and deployment.

Forge Biologics Announces Positive FBX-101 Clinical Trial Update in Patients with Krabbe Disease Identified by Newborn Screening Ahead of RUSP Vote

Retrieved on: 
Monday, January 29, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Mortality, Death, HSCT, Patient, Legislation, GALC, Advisory Committee, AAV, Psychosine, ESGCT, Data, Gene, DSM-IV codes, Neurodegenerative disease, Disease, Safety, Central nervous system, Sphingolipid, Physician, Krabbe disease, Cell, Human services, Parent, Nervous system, Clinical trial, Forge, Peripheral nervous system, Hematopoietic stem cell transplantation, Brain, UCBT, Pharmaceutical industry

Infantile Krabbe patients, often not diagnosed until after significant disease manifestations have occurred, typically die by the age of two if not treated by HSCT before symptoms are observed.

Key Points: 
  • Infantile Krabbe patients, often not diagnosed until after significant disease manifestations have occurred, typically die by the age of two if not treated by HSCT before symptoms are observed.
  • Previously published data have demonstrated that patients with Krabbe treated with HSCT demonstrate increased lifespan and stabilization of neurodegenerative disease in the central nervous system.
  • FBX-101, an investigational adeno-associated viral (AAV) gene therapy, has been designed to address the peripheral nerve disease not corrected by HSCT.
  • As a result, after a year of patient and foundation advocacy, Krabbe disease is again being voted on for potential inclusion on the RUSP.

Metabolon and Sheffield Institute for Translational Neuroscience Join Forces to Propel ALS Research and Biomarker Discovery

Retrieved on: 
Tuesday, January 23, 2024
Patient, MNDA, Research, MND, Partnership, Metabolomics, CSF, Translational neuroscience, University, Brain cell, Medicine, Motor neuron diseases, Cell, Plasma, Disease, Facial muscles, Fluid mechanics, Biomarker, Neurology, Nervous system, Metabolism, Diagnosis, Motor Neurone Disease Association, Pharmaceutical industry

MORRISVILLE, N.C., Jan. 23, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced a strategic partnership with the Sheffield Institute for Translational Neuroscience (SITraN) and A Multicentre Biomarker Resource Strategy in ALS (AMBRoSIA). The collaboration aims to explore novel pathogenic mechanisms of ALS that may expand therapeutic possibilities to a patient population in need of additional treatment options.

Key Points: 
  • Motor neuron diseases (MND), which include ALS, are progressive disorders that affect voluntary muscle control.
  • Currently, there is no cure for these diseases, and approximately 80% of people with ALS die within two to five years of diagnosis.
  • "Metabolon is thrilled to collaborate with SITraN, a leading institution in translational neuroscience, and AMBRoSIA.
  • Together, we aim to drive significant progress in ALS research and biomarker discovery, bringing us closer to effective diagnostic and therapeutic solutions for this challenging disease," said Karl Bradshaw, Chief Business Officer at Metabolon.

Metabolon and Sheffield Institute for Translational Neuroscience Join Forces to Propel ALS Research and Biomarker Discovery

Retrieved on: 
Tuesday, January 23, 2024
Patient, MNDA, Research, MND, Partnership, Metabolomics, CSF, Translational neuroscience, University, Brain cell, Medicine, Motor neuron diseases, Cell, Plasma, Disease, Facial muscles, Fluid mechanics, Biomarker, Neurology, Nervous system, Metabolism, Diagnosis, Motor Neurone Disease Association, Pharmaceutical industry

MORRISVILLE, N.C., Jan. 23, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced a strategic partnership with the Sheffield Institute for Translational Neuroscience (SITraN) and A Multicentre Biomarker Resource Strategy in ALS (AMBRoSIA). The collaboration aims to explore novel pathogenic mechanisms of ALS that may expand therapeutic possibilities to a patient population in need of additional treatment options.

Key Points: 
  • Motor neuron diseases (MND), which include ALS, are progressive disorders that affect voluntary muscle control.
  • Currently, there is no cure for these diseases, and approximately 80% of people with ALS die within two to five years of diagnosis.
  • "Metabolon is thrilled to collaborate with SITraN, a leading institution in translational neuroscience, and AMBRoSIA.
  • Together, we aim to drive significant progress in ALS research and biomarker discovery, bringing us closer to effective diagnostic and therapeutic solutions for this challenging disease," said Karl Bradshaw, Chief Business Officer at Metabolon.

Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting

Retrieved on: 
Wednesday, January 17, 2024
Senior, North American Neuromodulation Society, HFX, Patient, Medicine, PST, NANS, Pain management, University, Nervous system, Spinal cord stimulator, SCS, Chronic pain, Caesars Palace, Annual general meeting, Research fellow, University of Arkansas, Plenary session, Hertz, Dentistry

REDWOOD CITY, Calif., Jan. 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the company's HFX™ 10 kHz Therapy for patients with chronic pain. Results will be presented at the 2024 North American Neuromodulation Society (NANS) Annual Meeting held from January 18-21, 2024 at Caesars Palace Las Vegas.

Key Points: 
  • Results will be presented at the 2024 North American Neuromodulation Society (NANS) Annual Meeting held from January 18-21, 2024 at Caesars Palace Las Vegas.
  • A total of 25 scientific abstracts reviewing clinical results for 10 kHz Therapy™, including four podium presentations and 21 posters, will be presented at the conference.
  • "The growing body of clinical evidence from our 25 scientific abstracts displays the substantial benefits of 10 kHz Therapy and we look forward to continuing to treat underserved patient populations suffering from debilitating chronic pain."
  • The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.